A Randomized Trial to Investigate the Efficacy and Safety of Insulin Glargine in Hyperglycemic Acute Stroke Patients Receiving Intensive Care

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jun 2

PMID 34075142

Authors

Sung-Chun Tang

Shyang-Rong Shih

Shin-Yi Lin

Chih-Hao Chen

Shin-Joe Yeh

Li-Kai Tsai

Wei-Shiung Yang

Jiann-Shing Jeng

Affiliations

Soon will be listed here.

Abstract

This pilot, randomized, open-label controlled study compared the basal-bolus regimens of insulin glargine (IG) and neutral protamine Hagedorn (NPH) insulin in stroke patients with hyperglycemia receiving intensive care. The study recruited acute stroke patients requiring intensive care within 72 h (h) of onset and had blood glucose > 200 mg/dL. 50 patients received IG (n = 26) or NPH (n = 24) with added short-acting prandial regular insulin over a 72-h period. The primary end point was the percentage of glucose within 80-180 mg/dL assessed through continuous glucose monitoring. The baseline characteristics were comparable, except the IG had higher glucose pre-randomization than the NPH (290.69 ± 82.31 vs. 246.04 ± 41.76 mg/dL, P = 0.021). The percentage of time with glucose between 80 and 180 mg/dL was 45.88 ± 27.04% in the IG and 53.56 ± 22.89% in the NPH (P = 0.341) and the percentage of glucose reduction was 31.47 ± 17.52% in the IG and 27.28 ± 14.56% in the NPH (P = 0.374). The percentage of time with glucose < 60 mg/dL was 0.14 ± 0.49% in the IG and 0.47 ± 1.74% in the NPH. Poststroke outcomes were not significantly different. In conclusion, IG is safe and equally effective as an NPH-based basal-bolus regimen for acute stroke patients with hyperglycemia receiving intensive care.Trial registration ClinicalTrials.gov, NCT02607943. Registered 18/11/2015, https://clinicaltrials.gov/ct2/show/NCT02607943 .

References

Desilles J, Meseguer E, Labreuche J, Lapergue B, Sirimarco G, Gonzalez-Valcarcel J . Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. Stroke. 2013; 44(7):1915-23. DOI: 10.1161/STROKEAHA.111.000813. View

Lucidi P, Porcellati F, Rossetti P, Candeloro P, Cioli P, Marzotti S . Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care. 2011; 34(6):1312-4. PMC: 3114339. DOI: 10.2337/dc10-1911. View

Umpierrez G, Smiley D, Zisman A, Prieto L, Palacio A, Ceron M . Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007; 30(9):2181-6. DOI: 10.2337/dc07-0295. View

Nader N, Hamishehkar H, Naghizadeh A, Shadvar K, Iranpour A, Sanaie S . Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study. Diabetes Metab Syndr Obes. 2020; 13:671-678. PMC: 7073596. DOI: 10.2147/DMSO.S240645. View

Williams L, Rotich J, Qi R, Fineberg N, Espay A, Bruno A . Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology. 2002; 59(1):67-71. DOI: 10.1212/wnl.59.1.67. View

Oghazian M, Javadi M, Radfar M, Torkamandi H, Sadeghi M, Hayatshahi A . Effectiveness of regular versus glargine insulin in stable critical care patients receiving parenteral nutrition: a randomized controlled trial. Pharmacotherapy. 2015; 35(2):148-57. DOI: 10.1002/phar.1546. View

Hemphill 3rd J, Greenberg S, Anderson C, Becker K, Bendok B, Cushman M . Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015; 46(7):2032-60. DOI: 10.1161/STR.0000000000000069. View

Kreisel S, Berschin U, Hammes H, Leweling H, Bertsch T, Hennerici M . Pragmatic management of hyperglycaemia in acute ischaemic stroke: safety and feasibility of intensive intravenous insulin treatment. Cerebrovasc Dis. 2008; 27(2):167-75. DOI: 10.1159/000185608. View

Danne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A . A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes. 2013; 14(8):593-601. DOI: 10.1111/pedi.12051. View

10.

Perez A, Ramos A, Carreras G . Insulin Therapy in Hospitalized Patients. Am J Ther. 2019; 27(1):e71-e78. DOI: 10.1097/MJT.0000000000001078. View

11.

Lin S, Tang S, Tsai L, Yeh S, Shen L, Wu F . Incidence and Risk Factors for Acute Kidney Injury Following Mannitol Infusion in Patients With Acute Stroke: A Retrospective Cohort Study. Medicine (Baltimore). 2015; 94(47):e2032. PMC: 5058971. DOI: 10.1097/MD.0000000000002032. View

12.

Johnston K, Bruno A, Pauls Q, Hall C, Barrett K, Barsan W . Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019; 322(4):326-335. PMC: 6652154. DOI: 10.1001/jama.2019.9346. View

13.

Shimoyama T, Kimura K, Uemura J, Saji N, Shibazaki K . Elevated glucose level adversely affects infarct volume growth and neurological deterioration in non-diabetic stroke patients, but not diabetic stroke patients. Eur J Neurol. 2014; 21(3):402-10. DOI: 10.1111/ene.12280. View

14.

Mayeda L, Katz R, Ahmad I, Bansal N, Batacchi Z, Hirsch I . Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7039577. DOI: 10.1136/bmjdrc-2019-000991. View

15.

Powers W, Rabinstein A, Ackerson T, Adeoye O, Bambakidis N, Becker K . Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American.... Stroke. 2019; 50(12):e344-e418. DOI: 10.1161/STR.0000000000000211. View

16.

. 15. Diabetes Care in the Hospital: . Diabetes Care. 2018; 42(Suppl 1):S173-S181. DOI: 10.2337/dc19-S015. View

17.

Hsieh F, Lien L, Chen S, Bai C, Sun M, Tseng H . Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. Circulation. 2010; 122(11):1116-23. DOI: 10.1161/CIRCULATIONAHA.110.936526. View

18.

Chen W, Wang X, Liu F, Ma L, Chen J, You C . Association of blood glucose with 30-day mortality in patients with intracerebral hemorrhage undergoing neurosurgical treatment. Br J Neurosurg. 2020; 35(6):743-748. DOI: 10.1080/02688697.2020.1775784. View

19.

Dhital S, Shenker Y, Meredith M, Davis D . A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients. Endocr Pract. 2012; 18(5):712-9. PMC: 3671576. DOI: 10.4158/EP11371.OR. View

20.

Palaiodimou L, Lioutas V, Lambadiari V, Paraskevas G, Voumvourakis K, Tsivgoulis G . Glycemia management in acute ischemic stroke: current concepts and novel therapeutic targets. Postgrad Med. 2019; 131(7):423-437. DOI: 10.1080/00325481.2019.1651206. View